Atara Scoops Up FDA Orphan Drug Status for T-lymphocyte Candidate

Atara Biotherapeutics has won orphan drug designation for its T-lymphocyte product candidate activated against Epstein-Barr Virus for the treatment of patients with EBV post-transplant lymphoproliferative disorder following hematopoietic cell transplant or solid organ transplant.

The candidate is on track to start Phase 3 studies, according to the company.